Advances in complex therapeutics and drug delivery are opening new possibilities across drug development. They are also creating new questions for bioanalytical scientists.
Drawing on lessons from Veloxity’s work across human and animal health, including a recent collaboration supporting Toralgen’s oral peptide delivery platform, this article explores four considerations for animal health developers as therapeutic modalities and development programs become increasingly sophisticated.
Four considerations for animal health developers
• Complex therapeutics require fit-for-purpose bioanalysis. Sensitive methods and optimized LLOQs and calibration ranges can help sponsors maximize the information generated from limited samples.
• Drug delivery matters. Bioanalysis can help developers compare formulations and routes of administration and understand their impact on drug exposure.
• Species and matrix matter. Methods cannot always be transferred from one biological context to another without evaluation and adaptation.
• Earlier collaboration can pay off later. Bringing bioanalytical scientists into non-regulated development can help identify challenges and establish methods that better support later regulated work.
Planning an animal health development program?
Whether you’re evaluating a complex therapeutic, alternative formulation or route of administration, or preparing for regulated bioanalysis, early analytical planning can help you get more from your study data.
